ALX Oncology/$ALXO
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About ALX Oncology
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
Ticker
$ALXO
Sector
Primary listing
Employees
44
Headquarters
Website
ALX Oncology Metrics
BasicAdvanced
$78M
-
-$2.01
0.53
-
Price and volume
Market cap
$78M
Beta
0.53
52-week high
$2.27
52-week low
$0.40
Average daily volume
312K
Financial strength
Current ratio
2.399
Quick ratio
2.201
Long term debt to equity
20.824
Total debt to equity
34.837
Interest coverage (TTM)
-65.88%
Profitability
EBITDA (TTM)
-107.669
Management effectiveness
Return on assets (TTM)
-50.49%
Return on equity (TTM)
-118.95%
Valuation
Price to book
1.72
Price to tangible book (TTM)
1.72
Price to free cash flow (TTM)
-0.792
Free cash flow yield (TTM)
-126.22%
Free cash flow per share (TTM)
-1.818
Growth
Earnings per share change (TTM)
-32.12%
3-year earnings per share growth (CAGR)
-12.25%
What the Analysts think about ALX Oncology
Analyst ratings (Buy, Hold, Sell) for ALX Oncology stock.
ALX Oncology Financial Performance
Revenues and expenses
ALX Oncology Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ALX Oncology stock?
ALX Oncology (ALXO) has a market cap of $78M as of December 09, 2025.
What is the P/E ratio for ALX Oncology stock?
The price to earnings (P/E) ratio for ALX Oncology (ALXO) stock is 0 as of December 09, 2025.
Does ALX Oncology stock pay dividends?
No, ALX Oncology (ALXO) stock does not pay dividends to its shareholders as of December 09, 2025.
When is the next ALX Oncology dividend payment date?
ALX Oncology (ALXO) stock does not pay dividends to its shareholders.
What is the beta indicator for ALX Oncology?
ALX Oncology (ALXO) has a beta rating of 0.53. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.